Glaxo's HIV launches continue to shine; U.K. cost watchdog slaps conditions on BMS hep C treatment;

> New GlaxoSmithKline ($GSK) launches--including HIV drugs Tivicay and Triumeq--helped the company offset sliding sales of Advair/Seretide in Q2, it said. Video

> The U.K.'s cost watchdog has restricted use of Bristol-Myers Squibb ($BMY) hep C treatment Daklinza to patients with genotype 1 or 4 who have either had previous drug treatment or who can't receive interferon. Report

> Pfizer's ($PFE) new cancer fighter Ibrance now boasts 22% market share among patients with estrogen-receptor-positive, HER2-negative tumors--up from 10% last quarter, CEO Ian Read said Tuesday. More

> Marina Maher Communications has hired Matthew Anderson as EVP and CMO as its pharmaceutical business continues to expand. Report

And Finally... Fat cartoon characters may make children eat more, a new study says. More

Suggested Articles

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Disorder: The Rare Disease Film Festival is back and bigger than ever, set for a West Coast debut with 50 films this fall.